Literature DB >> 19174495

Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.

Kirsten Vollmer1, Husai Gardiwal, Bjoern A Menge, Oliver Goetze, Carolyn F Deacon, Wolfgang E Schmidt, Jens J Holst, Juris J Meier.   

Abstract

INTRODUCTION: Impaired secretion of glucagon-like peptide 1 (GLP-1) has been suggested to contribute to the deficient incretin effect in patients with type 2 diabetes. It is unclear whether this is a primary defect or a consequence of the hyperglycemia in type 2 diabetes. We examined whether acute hyperglycemia reduces the postprandial excursions of gastric inhibitory polypeptide (GIP) and GLP-1, and if so, whether this can be attributed to changes in gastric emptying. PATIENTS AND METHODS: Fifteen nondiabetic individuals participated in a euglycemic clamp and a hyperglycemic clamp experiment, carried out over 285 min. A mixed meal was ingested after 45 min. Plasma concentrations of glucose, insulin, C-peptide, glucagon, triglycerides, GIP, and GLP-1 were determined, and gastric emptying was assessed using a (13)C-octanoate breath test.
RESULTS: Glucose levels were 160 +/- 1 mg/dl during the hyperglycemic clamp experiments and 83 +/- 3 mg/dl during the euglycemia (P < 0.0001). Glucose infusion rates were higher during hyperglycemia, but meal ingestion led to a decline in glucose requirements in both experiments (P < 0.0001). Insulin and C-peptide levels were higher during the hyperglycemic clamp experiments (P < 0.0001), whereas glucagon levels were higher during euglycemia (P < 0.0001). The postprandial increases in GIP and GLP-1 concentrations were 46 and 52% lower during the experiments with hyperglycemia (P = 0.0017 and P = 0.021). Hyperglycemia also elicited a significant delay in gastric emptying (P < 0.0001).
CONCLUSIONS: Hyperglycemia acutely reduces the postprandial levels of GIP and GLP-1, possibly through a deceleration of gastric emptying. This supports the concept that reduced incretin levels in some patients with type 2 diabetes are a consequence rather than a cause of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174495     DOI: 10.1210/jc.2008-2197

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Research advances in metabolism 2016.

Authors:  Nikolaos Perakakis; Olivia M Farr; Dario Tuccinardi; Jagriti Upadhyay; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-11-06       Impact factor: 8.694

2.  Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.

Authors:  Georgios C Boronikolos; Björn A Menge; Nina Schenker; Thomas G K Breuer; Jan-Michel Otte; Sascha Heckermann; Freimut Schliess; Juris J Meier
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

Review 3.  Regulation of hepatic glucose uptake and storage in vivo.

Authors:  Mary Courtney Moore; Katie C Coate; Jason J Winnick; Zhibo An; Alan D Cherrington
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

4.  Contributions of fat and protein to the incretin effect of a mixed meal.

Authors:  Guillaume Carrel; Léonie Egli; Christel Tran; Philippe Schneiter; Vittorio Giusti; David D'Alessio; Luc Tappy
Journal:  Am J Clin Nutr       Date:  2011-08-17       Impact factor: 7.045

5.  Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.

Authors:  L Epprecht; S R Schreglmann; O Goetze; D Woitalla; C R Baumann; D Waldvogel
Journal:  J Neurol       Date:  2015-06-06       Impact factor: 4.849

6.  The effect on glucagon, glucagon-like peptide-1, total and acyl-ghrelin of dietary fats ingested with and without potato.

Authors:  Angela Radulescu; Mary C Gannon; Frank Q Nuttall
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

Review 7.  Metabolic Messengers: glucagon-like peptide 1.

Authors:  Fiona M Gribble; Frank Reimann
Journal:  Nat Metab       Date:  2021-01-11

Review 8.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

Review 9.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

10.  Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight.

Authors:  Fei Wang; Stephanie M Yoder; Qing Yang; Alison B Kohan; Tammy L Kindel; Jacob Wang; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-03       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.